Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co ( (HK:1349) ).
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. has announced a board meeting scheduled for October 30, 2025, to consider and approve the unaudited financial results for the third quarter ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
More about Shanghai Fudan Zhangjiang Bio Pharmaceutical Co
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative medicines. The company is known for its research-driven approach and commitment to advancing healthcare solutions.
Average Trading Volume: 18,256,511
Current Market Cap: HK$1.09B
Learn more about 1349 stock on TipRanks’ Stock Analysis page.